News | Artificial Intelligence | March 15, 2018

Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening

The collaboration will use Deep Learning techniques to establish medical imaging biomarkers for more accurate diagnosis

 

Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening

March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital (CHU de Nice) today announced a collaborative agreement that uses Artificial Intelligence to identify medical imaging biomarkers for lung cancer screening. These efforts will enable more accurate diagnosis and provide physicians with new therapeutic decision-making tools, based on medical imaging.

As part of the collaboration, medical imaging data from the AIR study - a French, multicenter cohort study, led by the Nice Hospital that has enrolled, to-date, more than 600 high-risk patients (smokers or former smokers with Chronic Obstructive Pulmonary Disease [COPD]) screened for lung cancer - will be analyzed to identify and characterize pulmonary nodules visible in thoracic CT scans. By using Deep Learning methods, a discipline of Artificial Intelligence, Median will develop new algorithms to identify imaging biomarkers that indicate pulmonary nodule malignity.

While current CT scan performance enables more pulmonary abnormalities to be identified, post-treatment image applications do not allow for an automatic, accurate characterization of the malignity or benignity of these pulmonary abnormalities. Lung nodule biopsies, which are invasive, are needed to confirm a diagnosis - potentially leading to complications for patients. By using medical imaging biomarkers, clinicians can reduce unnecessary biopsies and more accurately diagnose patients.

"Early detection of lung cancer is of paramount importance if we want to lessen mortality of this disease", says Professor Charles Marquette, coordinator of clinical teams in the AIR study. "The rationale for screening is based on the tight relationship between outcome and extent of the disease at time of diagnosis. However, large-scale screening of unselected population with chest computed tomography (CT) is expensive and has a high harm to benefit ratio, which explains why many health agencies are reluctant to implement screening of lung cancer with chest CT alone. We are developing a multimodal approach to lung cancer screening, including refinement of screening criteria (e.g. focus on COPD), non-invasive biomarkers and use of Artificial Intelligence to better characterize chest CT findings.”

"Today, many pulmonary biopsies are performed unnecessarily; Artificial Intelligence is going to make imaging, which represents non-invasive and less expensive procedures, an improved therapeutic decision-making tool. With Artificial Intelligence, imaging will help to identify patients who really need a biopsy and will contribute to advance clinical practice," said Peter Bannister, Chief Technology Officer at Median Technologies.

Related Content

What It's Going to Take for AI to go Mainstream

Image courtesy of Pixabay

Feature | Artificial Intelligence | April 18, 2018 | Paddy Padmanabhan
No technology concept is going to be more discussed, dissected or debated in healthcare this year than artificial int
This image, taken with Canon's Aquilion One, shows a lung with metastases from bowel cancer.

This image, taken with Canon’s Aquilion One, shows a lung with metastases from bowel cancer. Image courtesy of Canon.

Feature | Lung Cancer | April 18, 2018 | Jeff Zagoudis
In recent years, low-dose computed tomography (CT) screening has emerged as a proven, effective method to detect lung
FDA Clears Siemens' Somatom go.All, go.Top CT Scanners
Technology | Computed Tomography (CT) | April 18, 2018
The U.S. Food and Drug Administration (FDA) has cleared the Somatom go.All and Somatom go.Top computed tomography (CT)...
Carestream's Carbon Nano Tube Portable X-ray System Available for Order
News | Digital Radiography (DR) | April 17, 2018
Carestream Health is taking orders for its new Carestream DRX-Revolution Nano Mobile X-ray System in the United States...
Chest X-ray AI Algorithm Correctly Identifies Lung Disease for Dubai Health Authority
Feature | Artificial Intelligence | April 17, 2018
The Dubai Health Authority (DHA) announced the preliminary results of a chest X-ray artificial intelligence (AI)...
Philips Warns of Cybersecurity Vulnerabilities in IntelliSpace and iSite PACS Products
News | Cybersecurity | April 16, 2018
Philips Healthcare last week issued a proactive advisory warning to its iSite and IntelliSpace picture archiving and...
Canon Medical Systems' Aquilion Precision CT Receives FDA Clearance
Technology | Computed Tomography (CT) | April 13, 2018
April 13, 2018 — Canon Medical Systems USA Inc. this week received U.S.
Technology | Breast Density | April 13, 2018
Densitas Inc. has received U.S. Food and Drug Administration (FDA) clearance for its DENSITAS|density automated breast...
Local porters carried the Carestream Vita Flex CR system on their backs for 30 kilometers to Kunde Hospital

Local porters carried the Carestream Vita Flex CR system on their backs for 30 kilometers to Kunde Hospital

News | Computed Radiography (CR) | April 12, 2018
Capital Enterprises, a Carestream distributor, transported and installed a Carestream Vita Flex CR System that provides...
Overlay Init